Author:
Ralston Megan,Osman Alim,Suryadevara Pavan,Cleland Elissa
Abstract
Objective
Ketamine and esketamine have been used in the field of psychiatry to alleviate conditions such as major depressive disorder. Our objective was to evaluate the current literature on the use of ketamine for symptoms of social withdrawal in autism spectrum disorder (ASD) and autism-like conditions.
Methods
A comprehensive search of PubMed and Web of Science was conducted to identify literature involving the use of ketamine to treat symptoms of autism and social withdrawal. Patients with comorbid disorders were also included.
Results
Two original studies were found, showing mixed results on the use of ketamine for ASD. The use of esketamine found no statistically significant results, whereas the use of intravenous ketamine was shown to alleviate symptoms of social withdrawal especially in the short term. Neither study reported a significant amount of serious adverse events. Five case reports were also included, showing decreased depressive symptoms and evidence of increased social condition.
Conclusions
Research on the use of ketamine for ASD and ASD-related conditions is limited. Evidence of improved social condition exists, but further studies should be conducted to increase sample power and test various doses and methods of administration.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference40 articles.
1. Mechanisms of ketamine action as an antidepressant;Mol Psychiatry,2018
2. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms;Pharmacol Rev,2018
3. Ketamine as an anesthetic, analgesic and anti-depressant;Tijdschr Psychiatr,2020
4. Ketamine: a versatile tool for anesthesia and analgesia;Curr Opin Anaesthesiol,2020
5. Rethinking the paradigm: evaluation of ketamine as a neurosurgical anesthetic;AANA J,2012